Trial Number


Age range

90 days to 4 years


Male or Female

Enrolling Patients


In contrast to other contemporary treatment approaches to pediatric leukemia, current protocols for Acute Myeloid Leukemia in children with Down syndrome (DS AML) lack a risk-adapted stratification of treatment intensity. As a result, cycles of high-dose chemotherapy continue to be administered to all patients with DS AML. The majority of patients with DS AML have prognostically very favorable disease and do not benefit from high-intensity chemotherapy. Maximizing dose intensity has proved a successful strategy for the treatment of AML in the general pediatric population; however, intensive AML therapy protocols were optimized in the non-DS pediatric population and have shown adverse effects on this specific population of DS AML. Therefore, COG has pursued the rational development of treatment protocols specific for DS AML.

Principal Investigator

MemorialCare Research Center Contact Form

For further information about this study or to express your interest in this study, please fill out and submit this form.

Enter Trial number from the area just below the marquee.
How would you prefer to be contacted?
How did you hear about us?
This registration is for:
CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.